Revelation Biosciences (REVB)
NASDAQ:REVB
US Market
Holding REVB?
Track your performance easily

Revelation Biosciences (REVB) Income Statement

102 Followers

Revelation Biosciences Income Statement

Last quarter (Q2 2024), Revelation Biosciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Revelation Biosciences's net income was $-8.39M. See Revelation Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 9.14M$ 8.66M$ 10.86M$ 11.95M$ 2.53M
Operating Income
$ -9.14M$ -8.66M$ -10.86M$ -11.95M$ -2.53M
Net Non Operating Interest Income Expense
---$ -34.64K$ 84.00
Other Income Expense
$ 6.01M$ 8.54M$ -34.96K$ 36.35K-
Pretax Income
$ -15.15M$ -120.25K$ -10.83M$ -11.99M$ -2.53M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -15.17M$ -120.25K$ -10.83M$ -11.99M$ -2.53M
Basic EPS
$ -8.26$ -0.53$ -20.09$ -40.95$ -0.20
Diluted EPS
$ -8.26$ -0.53$ -20.09$ -40.95$ -0.20
Basic Average Shares
$ 14.83M$ 228.64K$ 539.04K$ 51.99K$ 12.94M
Diluted Average Shares
$ 14.83M$ 228.64K$ 539.04K$ 51.99K$ 12.94M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 9.14M$ 8.66M$ 10.86M$ 11.95M$ 2.53M
Net Income From Continuing And Discontinued Operation
$ -15.17M$ -120.25K$ -10.80M$ -11.99M$ -2.53M
Normalized Income
$ -12.10M$ -95.00K--$ -2.53M
Interest Expense
-----
EBIT
$ -15.15M$ -8.66M$ -10.83M$ -11.99M$ -2.53M
EBITDA
$ -15.12M$ -8.63M$ -10.80M$ 0.00$ -2.53M
Currency in USD

Revelation Biosciences Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis